Bausch + Lomb Corporation
BLCO
Positions held
Your positionsBLCO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Bausch + Lomb operates in the growing medical instruments and supplies sector, which is expected to expand as global healthcare demands increase.
- Revenue increased by 12% compared to the prior quarter, reaching $1.4 billion.
- Gross margin improved to 62.2%, up from 61.2% in the previous quarter.
- The company has a negative profit margin of -3.21%, indicating ongoing challenges in profitability.
- Net income for the latest quarter was -$14 million, continuing a trend of quarterly losses.
- The operating margin remains low at 7.7%, highlighting potential inefficiencies in operations.
Fundamentals
| Market cap | $6.13B | Enterprise value | $10.94B | Trailing P/E | — | Forward P/E | 15.40 |
| PEG | 0.89 | Price / book | 0.95 | Beta | 0.56 | Dividend yield | 0.00% |
| Revenue growth | 9.1% | Earnings growth | — | Gross margin | 61.4% | Operating margin | 7.7% |
| Profit margin | -3.2% | ROE | -2.5% | ROA | 1.8% | Debt / equity | 0.79 |
| Current ratio | 1.55 | Free cash flow | $323.00M | Analyst recommendation | buy | Mean target | $19.39 |
| 52w high | $18.92 | 52w low | $13.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.2B | $1.4B | $1.3B | $1.3B |
| Op margin | 7.7% | 4.7% | 11.2% | 6.2% | 0.9% |
| Net income | -$14.0M | -$71.0M | -$58.0M | -$28.0M | -$62.0M |
| Gross margin | 62.2% | 61.2% | 62.1% | 60.2% | 58.9% |
| Gross profit | $867M | $761M | $872M | $771M | $753M |
| Operating income | $108M | $59.0M | $158M | $80.0M | $11.0M |
- Revenue +12% vs prior quarter ($1.4B vs $1.2B).
- Gross margin 62.2% (was 61.2% prior quarter).
- Operating margin expanded to 7.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.1B | $4.8B | $4.1B | $3.8B | — |
| Op margin | 3.7% | 4.3% | 4.9% | 5.8% | — |
| Net income | -$360M | -$317M | -$260M | $6.0M | — |
| Gross margin | 59.8% | 60.9% | 60.4% | 59.7% | — |
| Gross profit | $3.1B | $2.9B | $2.5B | $2.2B | — |
| Operating income | $188M | $206M | $204M | $220M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says
2026-10-08 · 3 Low-Volatility Stocks with Open Questions
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Barclays Initiates Coverage on Bausch + Lomb With Overweight Rating, $24 Price Target
2026-10-06 · Bausch + Lomb Advances Oral Dry AMD Treatment Development
2026-10-06 · Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
2026-10-05 · Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
2026-10-01 · SpyGlass Pharma Acquires Advanced Vision Science for $13 Million
2026-09-17 · 3 Small-Cap Stocks That Concern Us
2026-09-16 · Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026
2026-09-14 · BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Price (daily)
Full chart · RSI · MACD · patterns